Goldman Sachs analyst Salveen Richter says big pharma is shopping in China biotech. This trend is driven by the imminent expiration of patents worth 440 billion dollars in drugs. This dynamic offers significant growth opportunities for Chinese companies in the sector.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
